Introduction
============

Angiogenesis refers to the form of new vascular network by the proliferation and migration from the original vascular endothelial cells [@B1]. Angiogenesis is essential both in the adult new blood vessel formation and in embryogenesis, while abnormal angiogenesis is related to certain pathological states such as cancer [@B2], [@B3]. During cancer growth, newly formed blood vessels are required to provide nutrients and oxygen, and remove the waste products [@B3], [@B4].

Among the regulators of angiogenesis, VEGF is the most potent stimulator in physiological and pathological situations [@B5], [@B6]. To promote angiogenesis, VEGF acts through its receptor VEGFR2, which is highly expressed in ECs [@B7]-[@B9]. VEGFR1, another receptor of VEGF, is considered to be a \'decoy\' receptor which isolates VEGF and reduces its incorporation to VEGFR2 [@B10]-[@B12]. Previous studies suggested that VEGFR1 suppresses the pro-angiogenic signals induced by VEGFR2 in ECs [@B13]. In addition, the soluble VEGFR1 which carries only the extracellular domain, is considered to be a natural inhibitor of VEGF-A [@B7].

Dihydroartemisinin (DHA) is a semi-synthetic derivative of artemisinin, which is extracted from Chinese herb Artemisia annua [@B14], [@B15]. Like other artemisinin derivatives, DHA displayed strong anti-inflammatory and anti-angiogenic activities [@B16]-[@B18]. Although DHA have a positive role in angiogenesis in zebrafish [@B19], it suppressed the growth, proliferation, migration, and tube formation of mammalian ECs, which are essential processes in angiogenesis [@B20]-[@B22]. In addition, DHA inhibited VEGF expression in cancer cells and reduced VEGF binding to its receptors in HUVECs [@B18], [@B23]. However, the role and mechanisms by which DHA affects VEGFR1 expression in ECs have not been studied.

ETS-1 is a member of the ETS transcriptional factor family which contains about 30 related proteins and a basic 80-90 aa DNA-binding domain [@B24]. As a transcription factor, ETS-1 is highly expressed in vascular system [@B25], [@B26]. In ECs, ETS-1 regulates downstream target genes including *Tie1*, *Tie2*, *MMPs*,*p53* and *VEGFR1* [@B27]-[@B30]. On the *VEGFR1* promoter, ETS-1 binds to a conserved ETS responsive element between -49 and -52 region to promote VEGFR1 expression [@B31].

In this study, we reported that DHA significantly upregulates the expression of VEGFR1 and ETS-1 in HUVECs. ChIP assays validated that the binding of ETS-1 on the *VEGFR1* promoter was significantly increased by DHA treatment. In addition, knockdown of ETS-1 eliminates DHA-induced expression of VEGFR1. These results indicated that DHA elevates VEGFR1 expression via up-regulation of ETS-1 in HUVECs.

Materials and Methods
=====================

Cell culture
------------

HUVECs were obtained from Lonza (Basel, Switzerland) and cultured in DMEM (Corning, NY, USA) with 10% FBS (Lonza), 100 IU/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA). HUVECs were treated with DHA (Sigma-Aldrich) for different time points (0, 1, 6, 12, 24 h) or concentrations (0, 5, 10, 25, 50, 100 μM).

Western blotting
----------------

After treatment with DHA, HUVECs were lysed in RIPA lysis buffer with 0.1% SDS, 1 mg/ml leupeptin and 1 mM PMSF on ice. Proteins were quantified by BCA assay (Bio‑Rad, Hercules, CA, USA). The protein samples were loaded and separated on a 8% SDS‑polyacrylamide gel, then electroblotted onto the PVDF membranes. The membranes were blocked 1 h in 5% skim milk in TBS-T (TBS containing 0.05% Tween-20), and then incubated with the primary antibody at 4˚C overnight. The primary antibodies include anti-VEGFR1 antibody (Abcam, Cambridge, MA, USA), anti-ETS-1 antibody (Abcam) and anti-β-actin antibody (Sigma-Aldrich). The membranes were washed in TBS-T, and incubated with a HRP-linked goat anti-rabbit secondary antibody (Proteintech, Chicago, IL, USA) for 2 h at room temperature. The protein bands were visualized with an ECL kit (Millipore, Billerica, MA, USA).

RNA extraction and quantitative real-time PCR(qRT-PCR)
------------------------------------------------------

Total RNA of HUVECs was isolated using Trizol (Invitrogen, Carlsbad, CA, USA), and the cDNAs was generated from the reverse transcription by the RevertAid First Strand cDNA Synthesis Kit (ThermoFisher, Grand Island, NY, USA). Then the mRNAs levels were evaluated by qRT-PCR executed by a Applied Biosystems PCR System (Waltham, MA, USA) with SYBR supermix (TaKaRa Biotechnology, Shiga, Japan) and following the thermocycling conditions: 94°C 1 min; 95°C 1 min; 95°C 12 s, 62 °C 1 min; 40 cycles from step 3 to 4. The primers are as follows: *VEGFR1*: sense, 5ˊ-TGGCCATCACTAAGGAGCACTCC-3ˊ; anti-sense, 5ˊ-GGAACTGCTGATGGCCACTGTG-3ˊ; *ETS-1*: sense, 5ˊ-TTCACTAAAGAACAGCAAC-3ˊ; anti-sense, 5ˊ-TGTCCCCAACAAAGTCTG-3ˊ; *β‑actin*: sense, 5ˊ-TTGCCGACAGGATGCAGAA-3ˊ; anti-sense, 5ˊ- GCCGATCCACACGGAGTACT-3ˊ. Results was normalized against *β‑actin.*

Immunofluorescence (IF)
-----------------------

HUVECs were grown fluency on cover glass. After DHA treatment, 4% paraformaldehyde was added to fix the cells. Then the cells were penetrated with Triton X-100 (0.1%) for 10 min and blocked with 5% BSA. Proteins were labeled with primary antibody against VEGFR1 (Abcam) at 4˚C overnight and an Alex-546 labelled anti-rabbit IgG secondary antibody (Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. The cell nucleus was stained with DAPI (ThermoFisher). Positive staining were detected using a fluorescence microscopy (Olympus, Tokyo, Japan).

Chromatin immunoprecipitation (ChIP)
------------------------------------

A ChIP assay Kit (Millipore) was used as previously described [@B32]. HUVECs were exposed to 1% paraformaldehyde for 10 min to achieve in vivo crosslinking, then the crosslinked DNA were sheared to 200-1000 bp fragments by sonication. The chromatin fragments were immunoprecipitated with antibodies against ETS-1 (Abcam) and IgG (Millipore) using protein A/G agrose beads. The immunoprecipitated gDNA was enriched by centrifuging and purified by Phenolic chloroform isoamyl alcohol (25:24:1). The immunoprecipitated fragments of the *VEGFR1* promoter were amplified by PCR. The primers are as follows: forward, 5ˊ-CCCTCGGCTGCTCTTCATC-3ˊ; reverse, 5ˊ-TTCCTCCCAGGCTCGCTTCC-3ˊ.

siRNA transfection
------------------

Transfection of siRNAs was performed when HUVECs were reached 60% confluent using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Briefly, transfection reagent was mixed with siRNAs (Genepharma, Shanghai, China) with Opti-MEM (Invitrogen) separately. The mixture were incubated for 20 min and added into the cell culture. The cells were collected 48 h later. The following siRNAs were used: *ETS-1* siRNA: sense, 5ˊ-AUAGAGAGCUACGAUAGUUdTT-3ˊ; anti-sense, 5ˊ-AACUAUCGUAGCUCUCUAUdTT-3ˊ; control siRNA: sense, 5ˊ-UUCUCCGAACGUGUCACGUTT-3ˊ; anti-sense, 5ˊ-ACGUGACACGUUCGGAGAATT-3ˊ.

Statistical analysis
--------------------

Statistical significance was evaluated with paired-sample *t*-test by using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). p\<0.05 was considered significant.

Results
=======

The effects of DHA on VEGFR1 expression in ECs
----------------------------------------------

HUVECs were treated with DHA at different dose and time course. We found that DHA remarkably increased the mRNA (Fig. [1](#F1){ref-type="fig"}A) and protein level (Fig. [1](#F1){ref-type="fig"}B) of VEGFR1 at a concentration of 50 µM and 100 µM. By treatment with 50 µM DHA, the mRNA and protein level of VEGFR1 was significantly increased in a time-dependent manner (Fig. [1](#F1){ref-type="fig"}C, D). Immunofluorescence staining with VEGFR1 antibody showed that the VEGFR1 expression on the EC membrane was remarkably increased by DHA treatment (Fig. [1](#F1){ref-type="fig"}E). Together, DHA increases VEGFR1 expression in HUVECs.

The effects of DHA on ETS-1 expression in ECs
---------------------------------------------

Because ETS-1 is a major regulator of VEGFR1 [@B33], [@B34], we next investigated the effects of DHA on expression of ETS-1. qRT-PCR analysis showed that the *ETS-1* mRNA expression levels were significantly increased by DHA treatment at 50 µM and 100 µM for 24 h (Fig. [2](#F2){ref-type="fig"}A). Western blot analysis showed a similarly pattern of increase of ETS-1 protein levels by 50 µM and 100 µM DHA treatment (Fig. [2](#F2){ref-type="fig"} B). At a concentration of 50 µM, DHA significantly increase the mRNA and protein levels of ETS-1 after 12 h and 24 h treatment (Fig [2](#F2){ref-type="fig"}C, D). These results indicated ETS-1 expression is enhanced during DHA treatment in HUVECs.

DHA enhances ETS-1 binding to the VEGFR1 promoter
-------------------------------------------------

Previously studies reported that the promoter of *VEGFR1* gene contains ETS binding motifs [@B29], [@B31], [@B34]. To examine the effects of DHA on the interactions between ETS-1 and *VEGFR1* promoter, HUVECs were treated with 50 µM DHA for 24 h and collected for CHIP assay. As shown on Fig. [3](#F3){ref-type="fig"}, ETS-1 binds to -52 ETS motif on the *VEGFR1* promoter (Fig. [3](#F3){ref-type="fig"}A) and DHA further enhanced the binding of ETS-1 to the motif (p\<0.05)(Fig. [3](#F3){ref-type="fig"}B).

Knockdown of ETS-1 eliminates DHA-induced expression of VEGFR1 in ECs
---------------------------------------------------------------------

To confirm the role of ETS-1 in DHA induced VEGFR1 expression, ETS-1 were knocked down in HUVECs by siRNA interference. Transfection of ETS-1 siRNA in HUVECs reduced both *ETS-1* (P\<0.01) (Fig. [4](#F4){ref-type="fig"}A) and *VEGFR1* transcription (P\<0.05)(Fig. [4](#F4){ref-type="fig"}B), and induced measureable decrease of ETS-1 (Fig. [4](#F4){ref-type="fig"}C) and VEGFR1 protein (Fig. [4](#F4){ref-type="fig"}D). Next, HUVECs with *ETS-1* siRNA transfection were treated with 50 µM DHA for 24 h. In the ETS-1-silenced HUVECs, no increase in VEGFR1 mRNA (Fig. [4](#F4){ref-type="fig"}E) and protein (Fig. [4](#F4){ref-type="fig"}F) was observed after DHA treatment. Therefore, DHA-induced elevation of VEGFR1expression is mediated by ETS-1.

Discussion
==========

DHA is an effective anti-malarial agent with few side effects [@B15], [@B20]. Recent studies revealed a potent anti-tumor and anti-angiogenic activity of DHA [@B35], [@B36]. On cellular level, DHA exerted a significant inhibitory effect on apoptosis, migration and tube-like formation of ECs [@B37]. Several signaling cascades including NF-κB, PKC, ERK, JNK, and p38 MAPK pathway have been reported to mediate the effects of DHA [@B38]-[@B42]. For example, DHA activates JNK signaling pathway and then increases the expression of cyclooxygenase-2 and matrix metalloproteinase-13 (MMP-13) [@B43]. Moreover, DHA plays a negative role in the expression of hypoxia inducible factor (HIF)-1α, angiogenic mediators VEGF, MMP9, MMP11, and collagens [@B30], [@B44]. Structurally, DHA may bind to VEGF and its receptors [@B45]. Although dozens of papers have been published regarding the role of DHA on endothelial cell function, to date the effects of DHA on VEGFR1 expression in ECs have not been reported. In this study, we found that transcriptional factor ETS-1 mediates dihydroartemisinin-induced VEGFR-1 expression. This novel finding was validated by mRNA and protein expression analyses, siRNA interference and examination of protein-DNA interactions.

VEGFR1 is a one of the major regulators in vascular development and angiogenesis [@B7], [@B46]. The responses of VEGFR1 are influenced by the binding of ligands and the indirectly interaction with VEGFR2 [@B7], [@B29]. Loss of VEGFR1 increases VEGFR2 phosphorylation and activity, resulting in vessel overgrowth [@B47], [@B48]. Overexpression of VEGFR1 suppresses VEGFR2-mediated EC proliferation [@B13], [@B49]. In addition, VEGFR1 directly mediates a series of signal responses during angiogenesis and might prevent tumor growth [@B48]. In this study, we demonstrated that DHA treatment significantly enhances the expression of VEGFR1, which may suppresses VEGFR2-mediated pro-angiogenic responses. Therefore, our study provided a novel mechanism of the anti-angiogenic effect of DHA.

ETS-1 is a master regulator of endothelial gene transcription [@B50]. The transcriptional regulation of VEGFR1 by ETS-1 during embryonic or tumorous angiogenesis has been systematically studied [@B33], [@B34]. Binding of ETS-1 on -52 site activates *VEGFR1* expression [@B51]. Our results showed that DHA significantly upregulates the expression of ETS-1 in HUVECs. ChIP assay also showed that DHA increases ETS-1 binding to the -52 ETS motif on the *VEGFR1* promoter. In addition, knockdown of ETS-1 abolished DHA-induced VEGFR1 expression. To our knowledge, this is the first study which validated the functional relevance between DHA and ETS-1. This suggest that ETS-1 as a novel mediator for the cellular functions of DHA and other artemisinin derivatives.

Although VEGFR-1 is highly expressed in ECs, it has also been detected in monocyte/macrophages, hematopoietic stem cells, and a subset of epithelial cancer cells [@B52], [@B53]. In other types of cells, VEGFR-1 also involves in regulation of cellular functions, e.g., it supports the growth and survival of human breast carcinoma [@B53]. ETS-1 is widely expressed in most cell types, and facilitates malignant transformation and tumour progression [@B54]. Therefore, ETS-1-regulated VEGFR-1 expression might exist in non-endothelial cells, which could also be effected by DHA treatment. Further studies are needed to explore the role of DHA on VEGFR-1 expression in non-endothelial cells, particularly in tumor cells.

In this study, we demonstrated that DHA induces VEGFR1 expression by up-regulating ETS-1 transcription factor. This is a novel mechanism contributing towards the effect of DHA on endothelium, and helps explore its clinical applications in chemotherapy.
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![**DHA up-regulates VEGFR1 expression in ECs.** (A) Relative *VEGFR1* mRNA expression in HUVECs treated with increasing concentrations of DHA for 24 h. n = 6; n.s., non-significant; \*, P \< 0.05; \*\*, P \< 0.01. (B) Representative immunoblots of VEGFR1 from HUVECs treated with increasing concentrations of DHA for 24 h. (C) Relative *VEGFR1* mRNA expression in HUVECs treated with 50 μM DHA at different time points. n = 5; n.s., non-significant; \*, P \< 0.05. (D) Representative immunoblots of VEGFR1 from HUVECs treated with 50 μM DHA at different time points. (E) Immunofluorescence staining of VEGFR1 in HUVECs treated with 50 μM DHA for 24 h.](jcav09p3366g001){#F1}

![**DHA up-regulates ETS-1 expression in ECs.** (A) Relative *ETS-1* mRNA expression in HUVECs treated with increasing concentrations of DHA for 24 h. n = 6; n.s., non-significant; \*, P \< 0.05; \*\*, P \< 0.01. (B) Representative immunoblots of ETS-1 from HUVECs treated with increasing concentrations of DHA for 24 h. (C) Relative*ETS-1* mRNA expression HUVECs treated with 50 μM DHA at different time points. n = 6; n.s., non- significant; \*, P \< 0.05; \*\*, P \< 0.01. (D) Representative immunoblot of ETS-1 from HUVECs treated with 50 μM DHA at different time points.](jcav09p3366g002){#F2}

![**DHA enhances ETS-1 binding to the*VEGFR1* promoter.** (A) ChIP assay for ETS-1 binding to *VEGFR1* promoter in HUVEC with 50 µM DHA treatment for 24 h. (B) Binding ratio relative to total input chromatin in the ChIP reaction. n = 6; n.s., non-significant; \*, P \< 0.05.](jcav09p3366g003){#F3}

![**Knockdown of ETS-1 eliminates DHA-induced expression of VEGFR1 in ECs.** HUVECs were transfected with control siRNA or siRNA against ETS-1. The expression of ETS-1 were assessed by qRT-PCR (A) and by Western blot (B). n = 4; \*, P \< 0.05; \*\*, P \< 0.01. After transfection, the expression of VEGFR1 were assessed by qRT-PCR (C) or by Western blot (D). HUVECs with ETS-1 siRNA interference were treated with 50 µM DHA. VEGFR1 expression was assessed by qRT-PCR (E) or by Western blot (F) at different time points. n = 6; n.s., non-significant.](jcav09p3366g004){#F4}
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